On Capitol Hill

RFK, Jr. Meets with Senators Ahead of Confirmation Hearings

Robert F. Kennedy Jr., President-elect Trump’s nominee for Secretary of the U.S. Department of Health and Human Services, has spent significant time on Capitol Hill meeting with both Republican and Democratic Senators in advance of his confirmation hearings. Kennedy has yet to receive any Senate Democratic endorsements. However, his meetings with Senate Republicans have been reported as mostly positive. Kennedy’s previous positions on vaccines, abortion, and food processing have been the focus of many of the conversations, and Republican Senators have characterized the nominee’s views on these issues as more reasonable than expected.

 

Chairman Crapo has announced that Kennedy’s hearing in Senate Finance will take place on January 29. While the Senate Finance Committee is responsible for advancing Kennedy’s nomination to the full Senate, the Senate Health, Education, Labor, and Pensions (HELP) Committee also plans to hear testimony from Kennedy next week.


Energy & Commerce Committee Holds Organizational Meeting

The House Energy & Commerce Committee – which has the broadest jurisdiction of any committee in Congress, including shared jurisdiction over the Medicare Program with the House Ways & Means Committee – convened their organization meeting for the 119th Congress on January 15. Newly appointed Committee Chair Brett Guthrie (R-KY) highlighted various health-related priorities that the committee will focus on in the new Congress, including lowering the cost of care, increasing price transparency, strengthening innovation, addressing the opioid epidemic, improving oversight of the Medicare and Medicaid Programs, and resorting trust in public health. The panel’s Health Subcommittee will be led by Chairman Buddy Carter, BSPharm (R-GA), and Ranking Member Diana DeGette (D-CO). Full subcommittee rosters can be viewed here (GOP) and here (Democrats).


Chair Carter Works to Advance Health Legislation

Representative Buddy Carter, BSPharm (R-GA), Chairman of the House Energy and Commerce Subcommittee on Health, stated that he is in talks to revive the health package included in the initial bipartisan government funding bill proposed last December. The package included a one-year, 3.53% increase to Medicare bonuses for alternative payment model participation, an increase to Medicare physician payments of 2.5% for 2025, and pharmacy benefit manager industry reforms, including delinking and rebate pass through for some medications under Medicare Part D.


Unfortunately, the healthcare provisions were ultimately removed from the package, which passed as a scaled back continuing resolution. Chair Carter has confirmed that he is in talks with House leadership about passing the health provisions as either a standalone bill or as a part of a budget reconciliation package. GOP Doctors Caucus Chair Greg Murphy, MD (R-NC) has also stated that consideration of the measure under suspension of the rules may also be a viable avenue.


MedPAC Recommends 1.3% Update for Medicare Physicians in CY 2026

The Medicare Payment Advisory Commission (MedPAC) last week voted on a physician payment update recommendation for Calendar Year (CY) 2026 of the Medicare Economic Index (MEI) minus 1%, which would result in an approximate 1.3% boost to account for inflation. The Commission also reiterated its previous recommendation to provide a safety-net payment for physicians providing care to low-income Medicare beneficiaries. The proposed update will be included in MedPAC's March Report to the Congress. Notably, the Commission is continuing to explore physician payment reforms more comprehensively, recognizing that a more holistic approach is needed to address the complex challenges facing the physician payment system.

Medicare Advantage, Part D Policies: CSRO & Coalition Partners Respond

This week, CSRO raised concerns regarding biosimilar reimbursement challenges in their response to CMS’s proposed CY 2026 Medicare Advantage and Part D rule. In their letter, CSRO explained how rebates offered by manufacturers to secure formulary placement artificially depress the average sales price (ASP) of biosimilars, leaving physician practices unable to afford these medications and patient's without access. Until Congress addresses the payment formula, they urged CMS to withdraw the 2018 step therapy memorandum to ensure patients can access an alternative therapy.


These concerns were also included in comments registered by CSRO’s coalition partner, the Alliance of Specialty Medicine, as well as the Underwater Biosimilars Coalition that CSRO co-leads with the American College of Rheumatology. In conjunction with the Alliance, CSRO also emphasized broader issues such as prior authorization burdens, equitable application of AI tools, and the need for robust network adequacy standards.

Read CSRO's Comments

Rheum for Action: Patients Before Monopolies Act: A Game Changer for Patients, Pharmacists, and Prices?

CSRO's Vice President of Advocacy & Government Affairs Dr. Madelaine Feldman discusses the difficulty in regulating the three big vertically integrated PBMs (Express Scripts, CVS Caremark, and OptumRx), and highlights a new piece of legislation, the Patients Before Monopolies (PBM) Act.


Read more in the latest edition of Rheum for Action, CSRO's advocacy column authored by Dr. Madelaine Feldman and produced in partnership with Rheumatology News (PDF available here).

Read Column

Happening Wednesday: AI & Rheumatology

Log in this upcoming Wednesday, January 29, at 7pm CT / 8pm ET for the first Business of Rheumatology seminar of 2025!


The program will feature a discussion on AI and rheumatology between CSRO’s Immediate Past President Dr. Gary Feldman and issue expert Dr. Jeffrey Curtis, and explore the effects of AI on practices, patient care, and the future of rheumatology. Sign up now!

Register

Legislation Around the Country

VA: Dr. Harry Gewanter Testifies on PDAB

On January 13, CSRO Board Member Dr. Harry Gewanter testified before the Assembly Labor and Commerce Committee expressing opposition to the state's proposed Prescription Drug Affordability Board (PDAB). Dr. Gewanter highlighted the unintended consequences of the PDAB, including patient access concerns and underwater reimbursement for medical practices that buy-and-bill. CSRO also submitted comments in opposition to the legislation in advance of the hearing. The bill was ultimately reported out of committee in a vote 12-Yay to 10-Opposed and was released to the Assembly Appropriations Health and Human Resources subcommittee. CSRO will remain engaged on the issue.

What's Happening in the States


CSRO tracks legislative activity relevant to the rheumatology community and their patients. Check out the list below to see the status of CSRO priority bills from the past two weeks, and click here to view a full status report of CSRO priority bills.


Be sure to check out our interactive legislative map tool for additional details.

View Full Status Report

Connecticut

  • Biomarker Testing Coverage (SB554): Introduced

 

Illinois

  • Prescription Drug Affordability Board (SB66): Introduced

 

Indiana

  • Copay Accumulator Adjustment Program Ban (SB435): Introduced

 

Maryland

  • Prescription Drug Affordability Board (SB357): Introduced
  • Prescription Drug Affordability Board (HB424): Introduced
  • Biosimilars (SB393): Introduced

 

Missouri

  • Copay Accumulator Adjustment Program Ban (SB45): Introduced

 

Nebraska

  • White Bagging (LB109): Introduced
  • Copay Accumulator Adjustment Program Ban (LB158): Introduced
  • Biomarker Testing Coverage (LB253): Introduced


 New York

  • 340B (S1913): Introduced


Oregon

  • 340B (SB533): Introduced
  • 340B (HB2385): Introduced
  • Prescription Drug Affordability Board (HB2599): Introduced

 

South Carolina

  • Alternative Funding Program Ban/Maximizer Program Ban (HB3575): Introduced
  • Alternative Funding Program Ban/Maximizer Program Ban (SB99): Introduced
  • Copay Accumulator Adjustment Program Ban (SB100): Introduced

 

Utah

  • 340B (SB69): Introduced

 

Virgina

  • Prescription Drug Affordability Board (HB1724): Assigned Approps sub: Health & Human Resources
  • Step Therapy (HB2258): Introduced
  • Biosimilars (HB2329): Introduced

 

Washington

  • Biomarker Testing Coverage (HB1062): Introduced

Mark Your Calendar: Upcoming Events

Business of Rheumatology: January 29, 2024

CSRO's virtual seminar series to help support rheumatology practices in building and strengthening their business.

CSRO Town Hall: February 10, 2024

Kick off the year with CSRO at this virtual meeting as we provide updates on our state policy priority issues and a 2025 legislative forecast.

CSRO Fellows Conference: February 21-23, 2025

An annual event to help rheumatology fellows prepare for their future roles as practicing rheumatologists.

CSRO Advocacy Conference: September 12-14, 2025

Mark your calendars to join us in Dallas, Texas, for CSRO's annual Advocacy Conference! 

State Society Conferences:

CSRO's state rheumatology society members host their own annual meetings throughout the year. Find a listing of these state-specific conferences on our website.

CSRO Resources for You

Action Center

Use CSRO's convenient online platform to easily find out who your elected officials are and engage with them directly.


Advocacy Council

Amplify your voice by assembling with other like-minded individuals to enhance CSRO’s advocacy initiatives.


Career Center

Locate the perfect fit whether you're looking for new career opportunities or trying to find the right candidate.


Explanatory Statement: “Underwater” Biosimilars

To aid in addressing the issue of "underwater" biosimilars with payers, CSRO has created a document to illustrate the extent of the problem.


Legislative Map Tool

Find your state on our interactive map tool to learn about current or proposed policy and ways you can take action to make an impact.


Payer Issues Reporting Form

Request assistance with any payer relation issues that may be impacting your patients or office.


Policy Correspondence

Easily access all of CSRO’s policy letters submitted to payers, state, and federal governments as an informational resource.


Rheum for Action

Learn about the latest advocacy issues in CSRO's advocacy column authored by Dr. Madelaine Feldman and produced in partnership with Rheumatology News.


Step Therapy Cover Sheets

Review CSRO's state-specific step therapy materials that help guide practices in gaining an exemption from step therapy protocols.

Questions?

Please visit the CSRO website for other news and updates, and do not hesitate to contact us with any questions at info@csro.info.

X  LinkedIn  Facebook  Email  Web